Overview

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With Immunoglobulin A Nephropathy on Stable RAAS Blockade

Status:
Completed

Trial end date:
2016-12-01

Target enrollment:

Participant gender:

Summary

This is a pilot study to test safety, tolerability, and efficacy of CCX168 in reducing proteinuria in patients with Immunoglobulin A nephropathy and persistent proteinuria despite supportive therapy with a maximally tolerated RAAS blocker.

Phase:

Phase 2

Details

Lead Sponsor:

ChemoCentryx

Treatments:

Antibodies
Immunoglobulin A
Immunoglobulins